Table 3 |
||||||||
|
Discontinuations of treatment in arthritis because of lack of efficacy or adverse events |
||||||||
|
Lack-of-efficacy discontinuations |
Adverse-event discontinuations |
|||||||
|
|
||||||||
|
Duration (weeks) |
Treatment |
Dose (mg/day) |
Number of events |
Total number |
Discontinuations, % (95% CI) |
Number of events |
Total number |
Discontinuations, % (95% CI) |
|
|
||||||||
|
2–6 |
Placebo |
339 |
1,925 |
17.6 (15.8–19.4) |
97 |
1,925 |
5.0 (4.0–6.0) |
|
|
Celecoxib |
<100 |
42 |
253 |
16.6 (12.1–21.1) |
8 |
253 |
3.2 (1.0–5.4) |
|
|
Celecoxib |
100 |
No data |
No data |
|||||
|
Celecoxib |
200 |
203 |
4,190 |
4.8 (4.2–5.4) |
223 |
4,190 |
5.3 (4.7–5.9) |
|
|
Celecoxib |
400 |
12 |
155 |
7.7 (3.6–11.8) |
5 |
155 |
3.2 (0.5–5.9) |
|
|
Celecoxib |
800 |
15 |
180 |
8.3 (4.2–12.4) |
14 |
180 |
7.8 (3.9–11.7) |
|
|
Paracetamol |
4,000 |
55 |
502 |
11.0 (8.3–13.7) |
27 |
502 |
5.4 (3.4–7.4) |
|
|
Rofecoxib |
25 |
19 |
1,191 |
1.6 (0.8–2.4) |
77 |
1,191 |
6.5 (5.1–7.9) |
|
|
Naproxen |
1,000 |
5 |
395 |
1.3 (0.1–2.5) |
31 |
395 |
7.8 (5.3–10.3) |
|
|
Diclofenac |
100/150 |
13 |
540 |
2.4 (1.0–3.8) |
51 |
540 |
9.4 (6.9–11.9) |
|
|
12 |
Placebo |
521 |
1,135 |
45.9 (43.0–48.8) |
70 |
1,135 |
6.2 (4.8–7.6) |
|
|
Celecoxib |
100 |
145 |
692 |
21 (18.1–23.9) |
52 |
692 |
7.5 (5.5–9.5) |
|
|
Celecoxib |
200 |
571 |
6,094 |
9.4 (8.6–10.2) |
488 |
6,094 |
8.0 (7.4–8.6) |
|
|
Celecoxib |
400 |
492 |
6,166 |
8.0 (7.4–8.6) |
590 |
6,166 |
9.6 (8.8–10.4) |
|
|
Celecoxib |
800 |
128 |
435 |
29.4 (25.1–33.7) |
28 |
435 |
6.4 (4.0–8.8) |
|
|
Paracetamol |
4,000 |
No data |
No data |
|||||
|
Rofecoxib |
25 |
1 |
132 |
0.8 (0.0–2.4) |
13 |
132 |
9.8 (4.7–14.9) |
|
|
Naproxen |
1,000 |
374 |
2,399 |
15.6 (14.2–17.0) |
316 |
2,399 |
13.2 (11.8–14.6) |
|
|
Diclofenac |
100/150 |
120 |
4,311 |
2.8 (2.2–3.4) |
338 |
4,311 |
7.8 (7.0–8.6) |
|
|
Ibuprofen |
2,400 |
14 |
345 |
4.1 (1.9–6.3) |
37 |
345 |
10.7 (7.4–14) |
|
|
24+ |
Placebo |
No data |
No data |
|||||
|
Celecoxib |
100 |
No data |
No data |
|||||
|
Celecoxib |
200 |
No data |
No data |
|||||
|
Celecoxib |
400 |
26 |
326 |
8.0 (5.1–10.9) |
34 |
326 |
10.4 (7.1–13.7) |
|
|
Celecoxib |
800 |
691 |
3,987 |
17.3 (16.1–18.5) |
892 |
3,987 |
22.4 (21–23.8) |
|
|
Paracetamol |
4,000 |
No data |
No data |
|||||
|
Rofecoxib |
25 |
No data |
No data |
|||||
|
Naproxen |
1,000 |
No data |
No data |
|||||
|
Diclofenac |
100/150 |
331 |
2,325 |
14.2 (12.8–15.6) |
593 |
2,325 |
25.5 (23.7–27.3) |
|
|
Ibuprofen |
2,400 |
456 |
1,985 |
23.0 (21.2–24.8) |
456 |
1,985 |
23.0 (21.2–24.8) |
|
|
|
||||||||
|
CI, confidence interval. |
||||||||
|
Moore et al. Arthritis Research & Therapy 2005 7:R644 doi:10.1186/ar1704 |
||||||||
